A Retrospective Look at Anti-EGFR Agents in Pancreatic Cancer Therapy
Henu K Verma1, Praveen K Kampalli2, Saikrishna Lakkakula3
1Stem Cell Laboratory, Institute of Endocrinology and Oncology, Naples, Italy.
Background:
The introduction of Monoclonal Antibodies (mAbs) and small-molecule Tyrosine Kinase Inhibitors (TKIs) that target the Epidermal Growth Factor Receptor (EGFR), marks a huge step forward in the Pancreatic Cancer (PC) therapy. However, anti-EGFR therapy is found to be successful only in a fraction of patients. Although anti-EGFR agents have shown considerable clinical promise, a serious adverse event associated with anti- EGFR therapy has been challenging. At this juncture, there is still more to be done in the search for effective predictive markers with therapeutic applicability.
Methods:
A focused literature search was conducted to summarize the existing evidence on anti-EGFR agents in pancreatic cancer therapy.
Results:
This review discusses various anti-EGFR agents currently in use for PC therapy and potential adverse effects associated with it. Existing evidence on EGFR TKIs demonstrated better tolerant effects and outcomes with multiple toxic regimens. Anti-EGFR therapy in combination with chemotherapy is necessary to achieve the best clinical outcomes.
Conclusion:
Future prospective studies on the identification of additional biological agents and novel anti-EGFR agents are warranted.
Insights
Anti-epidermal growth factor receptor (EGFR) therapies offer promise for pancreatic cancer (PC) but have limited success and side effects. Combination therapy and further research into predictive markers are crucial for improving outcomes.
Area of Science:
- Oncology
- Medical Science
Background:
- Epidermal Growth Factor Receptor (EGFR) inhibitors, including monoclonal antibodies (mAbs) and small-molecule Tyrosine Kinase Inhibitors (TKIs), represent advancements in Pancreatic Cancer (PC) treatment.
- However, the efficacy of anti-EGFR therapy is limited to a subset of patients, and associated adverse events pose challenges.
- There is an ongoing need for predictive markers to guide therapeutic application and improve patient selection.
Purpose of the Study:
- To review existing evidence on anti-EGFR agents in Pancreatic Cancer (PC) therapy.
- To summarize the efficacy, adverse effects, and potential combinations of anti-EGFR therapies for PC.
Main Methods:
- A focused literature search was performed to gather and synthesize current evidence on anti-EGFR agents in PC treatment.
Main Results:
- The review covers various anti-EGFR agents used in PC therapy and their associated adverse effects.
- Evidence suggests that EGFR TKIs may offer better tolerability and outcomes, particularly within complex toxic regimens.
- Combining anti-EGFR therapy with chemotherapy is indicated as essential for achieving optimal clinical results.
Conclusions:
- Further prospective studies are necessary to identify novel anti-EGFR agents.
- Research should focus on discovering additional biological markers to enhance the effectiveness of anti-EGFR therapies in Pancreatic Cancer.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:26Endoscopic Procedures V: ERCP
Patient...